

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): February 5, 2026**

**Zoetis Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35797**  
(Commission File  
Number)

**46-0696167**  
(I.R.S. Employer  
Identification No.)

**10 Sylvan Way Parsippany New Jersey**  
(Address of principal executive offices)

**07054**  
(Zip Code)

**(973) 822-7000**  
(Registrant's telephone number, including area code)

Not Applicable  
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	ZTS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

On February 5, 2026, the Company declared a dividend of \$0.53 per share for the second quarter of 2026. The dividend will be paid on June 2, 2026, to all holders of record of the Company's common stock as of the close of business on April 20, 2026.

The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	Press Release issued on February 5, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ZOETIS INC.**

Dated: February 5, 2026

By: /s/ Roxanne Lagano

Roxanne Lagano

Executive Vice President,

General Counsel and Corporate Secretary

**Media Contacts:**

Jennifer Albano

1-862-399-0810 (o)

[jennifer.albano@zoetis.com](mailto:jennifer.albano@zoetis.com)

Laura Panza

1-973-975-5176 (o)

[laura.panza@zoetis.com](mailto:laura.panza@zoetis.com)**Investor Contacts:**

Steve Frank

1-973-822-7141 (o)

[steve.frank@zoetis.com](mailto:steve.frank@zoetis.com)

Nick Soonthornchai

1-973-443-2792 (o)

[nick.soonthornchai@zoetis.com](mailto:nick.soonthornchai@zoetis.com)**Zoetis Declares Second Quarter 2026 Dividend**

PARSIPPANY, N.J. – February 5, 2026 –The Board of Directors of [Zoetis Inc.](#) (NYSE:ZTS) has declared a dividend of \$0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026.

**About Zoetis**

As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of \$9.3 billion in 2024 with approximately 13,800 employees. For more information, visit [www.zoetis.com](http://www.zoetis.com).

**DISCLOSURE NOTICES****Forward-Looking Statements:**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements include, but are not limited to, statements which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at [www.sec.gov](http://www.sec.gov), [www.zoetis.com](http://www.zoetis.com), or on request from Zoetis.

ZTS-COR  
ZTS-IR  
ZTS-FIN